ALK-positive solid tumors - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image of ALK-positive cancer cells and neladalkib targeted therapy, highlighting Nuvalent’s precision oncology approach beyond NSCLC.

Read More

6 minute read

Pharma Industry News

Nuvalent’s neladalkib posts 44% response rate in ALK-positive solid tumors beyond lung cancer

Discover how Nuvalent’s neladalkib delivered a 44% response rate in ALK-positive solid tumors beyond NSCLC and what this means for oncology.

October 19, 2025

web analytics